Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Scuola Medica - Via Roma 55, 56126, Pisa, Italy.
Med Oncol. 2020 Feb 27;37(3):19. doi: 10.1007/s12032-020-1345-2.
Anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid cancer, and novel therapies are urgently needed to prolong patient survival and improve clinical outcomes. Very few scientific reviews have examined the literature on combination therapies with the goal of describing the available preclinical and clinical data and suggesting future clinical combination treatment schedules. The present review focuses on preclinical and clinical studies of drug combination therapies in ATC. The relevant literature from PubMed and Scopus was reviewed in this article; the ClinicalTrials.gov database was searched for clinical trials not yet published. Recent data from preclinical models strongly support the idea that combination treatments that utilize drugs from different antineoplastic classes have synergistic antitumour activity in ATC. However, rapid translation of these therapies into the clinic is impeded by the difficulty in recruiting enough patients for randomized clinical trials. Although promising results have been obtained in preclinical studies, additional clinical research is required to elucidate the efficacy of combination treatments for clinical practice.
间变性甲状腺癌 (ATC) 是最具侵袭性的甲状腺癌，迫切需要新的治疗方法来延长患者的生存时间并改善临床结局。很少有科学综述检查过联合治疗的文献，旨在描述现有的临床前和临床数据，并提出未来的临床联合治疗方案。本文重点介绍 ATC 的药物联合治疗的临床前和临床研究。本文综述了来自 PubMed 和 Scopus 的相关文献，并在 ClinicalTrials.gov 数据库中搜索了尚未发表的临床试验。来自临床前模型的最新数据强烈支持这样一种观点，即利用不同抗肿瘤类别的药物进行联合治疗在 ATC 中具有协同抗肿瘤活性。然而，由于难以招募足够的患者进行随机临床试验，这些治疗方法迅速转化为临床治疗受到阻碍。尽管在临床前研究中取得了有希望的结果，但仍需要进一步的临床研究来阐明联合治疗对临床实践的疗效。
